파톰 파마슈티컬스(PHAT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $7.54 (-2.71%), 시가총액 $0.95B, 52주 최저~최고 $3.90 ~ $18.08.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey
파톰 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
파톰 파마슈티컬스의 현재 주가는 $7.54 (-2.71%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
파톰 파마슈티컬스의 시가총액은 약 $0.95B입니다.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has com